Evidence map›Paper›PMID 42863888›Full record

ArticleLupus science & medicine2026

Suboptimal attainment of SLE treat-to-target goals based on persistently high physician global assessment: an analysis of German SPOCS patients.

Martin Aringer, Peter Korsten, Tobias Alexander, Falk Hiepe, Marc Schmalzing, Lioba Pieterse, Mareike Giefer, Julius Brandenburg, Bo Ding, Julia Weinmann-Menke

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Lupus science & medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Martin AringerDivision of Rheumatology, Department of Medicine III, TUD Dresden University of Technology Faculty of Medicine Carl Gustav Carus, Dresden, SN, Germany Martin.Aringer@uniklinikum-dresden.de.ORCID http://orcid.org/0000-0003-4471-8375
Peter KorstenDepartment of Rheumatology and Clinical Immunology, St Josef-Stift Sendenhorst, Sendenhorst, Germany.ORCID http://orcid.org/0000-0001-6065-5680
Tobias AlexanderDepartment of Rheumatology and Clinical Immunology, Charite - Universitatsmedizin Berlin, Berlin, BE, Germany.
Falk HiepeDepartment of Rheumatology and Clinical Immunology, Charite - Universitatsmedizin Berlin, Berlin, BE, Germany.
Marc SchmalzingDepartment of Medicine II, Rheumatology and Clinical Immunology, Universitätsklinikum Würzburg, Würzburg, BY, Germany.
Lioba PietersePrivate Practice for Nephrology, Rheumatology, and Hypertension, Heidelberg, Germany.
Mareike GieferMedical Affairs Immunology, AstraZeneca GmbH, Hamburg, Germany.
Julius BrandenburgMedical Affairs Immunology, AstraZeneca GmbH, Hamburg, Germany.
Bo DingAstraZeneca Sweden, Mölndal, Sweden.ORCID http://orcid.org/0000-0001-9131-4563
Julia Weinmann-MenkeDepartment of Internal Medicine, Division of Nephrology, Johannes Gutenberg University Hospital Mainz, Mainz, Germany.ORCID http://orcid.org/0000-0001-7344-8381

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Interferon Type ILupus Erythematosus, SystemicOutcome Assessment, Health Care

Identifiers

PMID42863888
PMCPMC13662087

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.